Katherine Reeder-Hayes, MD, MBA, MSc, described the potential role of real-world evidence as a compliment to clinical trials as well as successful implementation of Big Data for real-world evidence generation.
On Saturday afternoon, the ASCO town hall convened to share different perspectives on administrative burden, pharmacy benefit managers, and clinical pathways.
In a session Saturday morning, Artia Hurria, MD, FASCO, detailed the current state of treatment for older patients with cancer and the reasons why further efforts are needed to improve the evidence base in this population.
James Lin Chen, MD, discussed the various challenges and considerations of enabling precision medicine with health information technology.
JCP is the official journal of the Clinical Pathways Congress meeting.
Gastric cancer screening could be cost-effective in high-risk racial and ethnic groups in the US, according to a new modeling study.
The National Comprehensive Cancer Network has released updated guidelines for the staging, primary evaluation, and surgical management of bladder cancer.
Gary Lyman, MD, MPH, co-director of the Hutchinson Institute for Cancer Outcomes Research (HICOR) discusses the inspiration, key findings, and overall goals of HICOR’s first-of-its-kind community cancer care report, “Community Cancer Care in Washington State: Quality and Cost Report.”
A recent review proposes a new form of research that includes cancer researchers as the primary drivers of the process and outlines the benefits of the model in relation to potential improved cost benefits.
Comparative Effectiveness Study Examines Safety, Efficacy of Biosimilar in Clinical Trial, Real-World Practice
The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer.